Enesi & Sementis team up on needle-free peanut allergy & zika vaccines

Enesi Pharma has entered into an R&D agreement with Australian biotech Sementis aimed to needle-free solid dose vaccines for peanut allergy as well as Zika infection.

The collaboration is focused on the development and evaluation of solid dose versions of Sementis’ lead peanut hypoallergy vaccine and its single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma’s ImplaVax technology.

ImplaVax is a proprietary needle-free solid dose implant and device technology for subcutaneous vaccination.

Data to date demonstrate that ImplaVax-enabled vaccines can deliver superior immune responses compared to standard injection protocols among other benefits such as safety, ease of use, reliability and stability.

Sementis’ investigational peanut hypoallergy vaccine – based on its SCV vector platform – has completed proof-of-concept studies, providing compelling evidence that it offers the possibility of a permanent cure for peanut allergy.

It is estimated that over seven million individuals suffer with serious allergy to peanut, including many children, in the major markets of the US, Europe and Japan. This represents an estimated cost to healthcare systems in the tens of billions of US dollars annually.

An ImplaVax-enabled vaccine could provide a simple and effective means to address peanut allergy on a large scale, particularly for younger sufferers who may have an aversion to needles and traditional injections.

Sementis’ single vectored vaccine for chikungunya/Zika virus infection is equally promising with extensive proof-of-concept studies in mice demonstrating the effectiveness of the vaccine in protecting against Zika and chikungunya from a single vaccination shot.

An ImplaVax-enabled product using the Sementis SCV chikungunya/Zika vaccine offers the potential to provide long-lasting immunity and retain potency across a wide range of storage conditions for prolonged periods.

Enesi Pharma will formulate solid dose implants based on SCV vaccine provided by Sementis, who will undertake safety and immunogenicity testing, and preclinical development.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...